Everyday grocery lists can mean everything to families facing dementia because they preserve independence while revealing where practical help is needed. They turn an overwhelming condition into a manageable question: what support will help this person shop and eat? Dementia is a loss of thinking and behavioral abilities severe enough to interfere with daily life. When shopping becomes difficult, a small piece of paper can carry far more weight than the items written on it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What a grocery list can show
- How families can support the task
- When does the family need a new plan?
- Does the new at-home treatment change daily care?
- What should families check before considering lecanemab?
What a grocery list can show
A list moves part of the planning task onto paper. It records intended meals, missing staples, and the next steps needed to keep food available. Consider a list containing milk, cereal, soup, and fruit.
The meaningful question is not whether the list looks tidy. It is whether the person can create it, remember it, find the items, and bring the groceries home. One unfinished shopping trip does not diagnose dementia or explain why something went wrong. Look instead for a pattern: repeated omissions, lists that are no longer used, or growing reliance on another person to complete the task.
How families can support the task
The goal is not necessarily to take over shopping. It is to provide the least help that still produces a reliable result.
The National Institute on Aging recommends written lists and suggests grocery delivery, simple meals, or community meal services when shopping becomes harder. Its practical guidance for living alone with early-stage dementia offers families a useful starting point. A workable routine might include:.
- Make the list together and connect each item to a meal.
- Decide who will shop, accompany the person, or place an order.
- Check that groceries arrived and were put away.
- Shift to delivery, simpler meals, or meal services when the list no longer provides enough support.
When does the family need a new plan?
Judge the system by what happens after the list is written. If suitable food regularly reaches the kitchen and the person can use it, the list may still be enough. If the list is made but shopping remains unfinished, add one specific layer of help.
That might mean a reminder before the trip, shopping together, or having someone place the order. Keep brief notes when the pattern changes. Record the date, what went wrong, and what help allowed the task to succeed. These concrete examples can make a clinical conversation clearer than saying only that shopping has become "more difficult.".
Does the new at-home treatment change daily care?
On July 13, 2026, the FDA approved Leqembi IQLIK, an under-the-skin form of lecanemab with a starting regimen that a patient or caregiver can begin at home. However, the evidence applies to adults with Alzheimer's disease whose trials involved confirmed amyloid pathology and either mild cognitive impairment or mild dementia, according to the FDA approval notice. That boundary matters. The approval is not evidence that lecanemab helps every type or stage of dementia, including later-stage or unconfirmed disease.
In the 18-month Clarity AD trial, participants receiving intravenous lecanemab changed by 1.21 points on the CDR-SB clinical scale, compared with 1.66 for placebo. The difference was −0.45 points, showing slower average decline rather than restored function, as reported in the published trial. The under-the-skin formulation was not separately tested in a large clinical-outcome trial. The FDA relied on established intravenous evidence, comparable drug exposure, and amyloid reduction.
What should families check before considering lecanemab?
At-home administration does not make treatment simple or suitable for everyone. Families still need a clinician to address eligibility, safety, monitoring, and access.
Important checks include: Medicare coverage is tied to a qualifying mild cognitive impairment or mild Alzheimer's diagnosis and Coverage with Evidence Development, including registry data submission. It is not automatic for every person with dementia, as explained in CMS's Medicare coverage guidance. Keep the current grocery list, note what help was needed to complete the shop, and take those examples to the next clinical visit.
- Confirm that the diagnosis and disease stage match the studied population.
- Ask how amyloid pathology will be confirmed.
- Discuss the boxed warning for ARIA, which can involve serious brain swelling or bleeding.
- Ask about recommended ApoE ε4 testing and the added caution needed with anticoagulants.
- Verify coverage rather than assuming FDA approval guarantees access.
